Merz’ IncobotulinumtoxinA Begins Phase 3 MINT Trials for Migraine Prevention
Merz initiates phase 3 trials for Xeomin, targeting migraine prevention in adults, aiming to fill gaps in current treatment options.
Previous Post
COVID-19 Vaccine Booster Receives Approval With Limits on Patient Access
Next Post
Missed Opportunities for Salpingectomy Highlight Gaps in Ovarian Cancer Prevention
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago